Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of three probabilistic antibiotic strategies on gut microbiota in prosthetic osteoarticular infection
2024-513298-29-00Phase 2Authorised
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Feb 2025
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of cefepime, piperacillin + tazobactam, ceftobiprole medocaril and daptomycin in osteomyelitis (OM) and Osteitis (3 arms), sponsored by Centre Hospitalier Universitaire de Nice. Primary endpoint: Gut microbiota biodiversity. Planned start Feb 2025; status: authorised.
02
Drugs
cefepimepiperacillin + tazobactamceftobiprole medocarildaptomycin
03
Conditions
osteomyelitis (OM)Osteitis
Beyond the preview
Go deeper on 2024-513298-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513298-29-00.